Author

Susanne Schultz

Observed name: Susanne E. Schultz

Institutions: LMU Klinikum, German Center for Infection Research, Institut für Infektions- und Tropenmedizin, Ludwig-Maximilians-Universität München

Observed institutions: Northwell Health, LMU Klinikum, German Center for Infection Research, Institut für Infektions- und Tropenmedizin, Ludwig-Maximilians-Universität München

ORCID: 0000-0002-2376-3292

Observed ORCID: 0000-0002-2376-3292

OpenAlex ID: A5032647657

Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial

2025 · Norbert Heinrich, Veronique de Jager, et al. · The Lancet Microbe · 30

Clinical Mortality in a Large COVID-19 Cohort: Observational Study

2020 · Mark P. Jarrett, Susanne E. Schultz, et al. · Journal of Medical Internet Research · 17

BTZ-043 Shows Good Safety and Strong Bactericidal Activity in a Combined Phase1b/2a Study in Tuberculosis Patients

2023 · Norbert Heinrich, Veronique De Jager, et al. · SSRN Electronic Journal · 5

Works count: 3

Citation count: 52

H-index: 3

I10-index: 2